<SEC-DOCUMENT>0001636282-25-000022.txt : 20250227
<SEC-HEADER>0001636282-25-000022.hdr.sgml : 20250227
<ACCEPTANCE-DATETIME>20250227160740
ACCESSION NUMBER:		0001636282-25-000022
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250227
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250227
DATE AS OF CHANGE:		20250227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Spyre Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001636282
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				464312787
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37722
		FILM NUMBER:		25678736

	BUSINESS ADDRESS:	
		STREET 1:		221 CRESCENT STREET
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		6176515940

	MAIL ADDRESS:	
		STREET 1:		221 CRESCENT STREET
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aeglea BioTherapeutics, Inc.
		DATE OF NAME CHANGE:	20150311
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>syre-20250227.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:54931160-13e1-4cff-902e-afae7a4c5b0d,g:a98c0da1-7b90-44ac-a2da-2ee51b9ca29c,d:cc6a6a0b5765435c941a0afc7dec0bb1-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>syre-20250227</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-24">0001636282</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="syre-20250227.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636282</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-27</xbrli:startDate><xbrli:endDate>2025-02-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="icc6a6a0b5765435c941a0afc7dec0bb1_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">February 27, 2025</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">SPYRE THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37722</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">46-4312787</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">221 Crescent Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Building 23</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine3" id="f-9">Suite 105</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Waltham</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">02453</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">617</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">651-5940</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-18">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:38.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-19">Common Stock, $0.0001 Par Value Per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-20">SYRE</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-21">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Nasdaq Global Select Market)</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icc6a6a0b5765435c941a0afc7dec0bb1_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2025, Spyre Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December&#160;31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="icc6a6a0b5765435c941a0afc7dec0bb1_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Exhibits</span></div><div style="margin-top:6pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:13.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="spyre-20241231xexx991.htm">Press release issued by Spyre Therapeutics, Inc. regarding its financial results for the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="spyre-20241231xexx991.htm">fourth </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="spyre-20241231xexx991.htm">quarter</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="spyre-20241231xexx991.htm"> and year</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="spyre-20241231xexx991.htm"> ended December 31, 2024 dated February 27, 2025.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icc6a6a0b5765435c941a0afc7dec0bb1_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">SPYRE THERAPEUTICS, INC.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 27, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Scott Burrows</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scott Burrows</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>spyre-20241231xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i6bf35f1a0c9f44d5aa5c1c90e163221e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:12pt;text-align:center"><img alt="spyre-logoxhorizontalxfulla.jpg" src="spyre-logoxhorizontalxfulla.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div><div style="margin-top:30pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reported positive interim pharmacokinetic (&#34;PK&#34;) and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million public offering</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Continued execution towards expected milestones across portfolio, with interim Phase 1 data readouts for SPY002 and SPY003 on-track for the second quarter and second half of 2025, respectively</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Remain on track for initiation of Phase 2 platform trial in ulcerative colitis (&#34;UC&#34;) in mid-2025 with SPY001 (&#945;4&#946;7), followed by SPY002 (TL1A), SPY003 (IL-23), and combinations thereof, with initial monotherapy results expected in 2026</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Announced indication expansion into rheumatoid arthritis (&#34;RA&#34;) with SPY002, with expected Phase 2 trial initiation in mid-2025 and top-line results in 2026</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">$603 million of cash, cash equivalents, and marketable securities as of December&#160;31, 2024, with expected runway into the second half of 2028</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Waltham, Mass, February 27, 2025 -</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Spyre Therapeutics, Inc. (&#34;Spyre&#34; or the &#34;Company&#34;) (NASDAQ&#58;SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of inflammatory bowel disease (&#34;IBD&#34;) and other immune-mediated diseases, today announced its fourth quarter and full year 2024 financial results and provided program and corporate updates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;In 2024, we initiated first-in-human studies for three of our next-generation antibodies and delivered outstanding interim Phase 1 results for SPY001, which underscore our portfolio's potential to revolutionize the treatment of IBD. Looking ahead, we are progressing our suite of therapeutics into a groundbreaking Phase 2 platform study in ulcerative colitis, which is designed to test both monotherapies and combination therapies with the potential for unified quarterly subcutaneous dosing in maintenance,&#34; said Cameron Turtle, DPhil., Chief Executive Officer. &#34;Additionally, the expansion of SPY002 into a Phase 2 rheumatoid arthritis trial this year represents a key step in addressing a pressing unmet need in a disease that affects millions across the globe. We are well-positioned and well-capitalized to deliver a series of value-inflecting catalysts, including three Phase 1 readouts expected in 2025 and four Phase 2 proof-of-concept readouts expected in 2026.&#34;  </font></div><div><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Development Pipeline Overview and Update</font></div><div style="margin-top:3pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company's approach combines best-in-class antibody engineering, dose optimization, and rational therapeutic combinations with the goal of maximizing efficacy, safety, and convenience in the treatment of IBD and other immune-mediated diseases. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders&#58; UC and Crohn's disease (&#34;CD&#34;). In the United States, it is estimated that approximately 2.4 million individuals are diagnosed with IBD. RA is a chronic inflammatory autoimmune condition that primarily affects the joints but also other parts of the body. It is characterized by pain, stiffness, and swelling of one or more joints and can progress from mild swelling of the joints in early </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">stages to severe deformations of the feet, ankles, and hands in late&#47;severe stages. RA affects more than 1.5 million individuals in the United States.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company has four programs in nonclinical and clinical development, three of which are targets in IBD validated by third parties. The fourth program is an undisclosed target. All three validated targets offer the potential for safe and effective treatment of UC and CD, with infrequent, subcutaneous maintenance dosing as a monotherapy or in rational combinations. The Company is also planning to study its anti-TL1A program in additional indications outside IBD, beginning with RA. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SPY001</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; a highly potent and selective investigational monoclonal antibody targeting &#945;4&#946;7, engineered with half-life extension technology and formulated at high concentration with the goal of maximizing efficacy and enabling infrequent, subcutaneous maintenance dosing.</font></div><div><font><br></font></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:35.03pt">In November 2024, interim healthy volunteer data from a Phase 1 trial were presented, demonstrating a favorable safety profile, a meaningfully differentiated PK profile relative to vedolizumab with half-life estimates greater than 90 days supporting potential Q6M maintenance dosing, and complete occupancy of &#945;4&#946;7 receptors out to 12 weeks at a single dose of 300mg. </font></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:35.03pt">Longer-term data from this Phase 1 trial will be presented at a medical meeting later this year. Based on these interim results, Spyre plans to advance SPY001 to a Phase 2 clinical trial in UC patients in mid-2025. </font></div><div style="text-indent:-4.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">SPY002</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#8211; a program with two highly potent and selective, investigational anti-TL1A monoclonal antibodies, engineered with half-life extension technology and formulated at high concentration with the goal of maximizing efficacy and enabling infrequent, subcutaneous maintenance dosing. The Company believes TL1A has emerged as one of the most promising targets in IBD and broader immunology indications.</font></div><div><font><br></font></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:35.03pt">In January 2025, the Company announced its intent to study one of its anti-TL1A antibodies in RA, with Phase 2 trial initiation expected in mid-2025 and topline results in 2026. With class-leading potency and half-life established in preclinical studies, SPY002 has the potential to become the first-in-class and best-in-class anti-TL1A treatment for RA.</font></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:35.03pt">In December 2024, the Company initiated first-in-human (&#34;FIH&#34;) trials of both SPY002 candidates, with healthy volunteer interim data expected in the second quarter of 2025. If successful, the Company expects one or more SPY002 candidates would then advance to Phase 2 clinical trials.</font></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:35.03pt">In October 2024, preclinical data for both SPY002 development candidates were presented at the United European Gastroenterology Week (&#34;UEGW&#34;) Congress demonstrating superior or comparable in vitro potency to first-generation anti-TL1As, as well as a pharmacokinetic half-life of 24 days in non-human primates (&#34;NHPs&#34;), which represents a two to three-fold increase compared to these same first-generation anti-TL1As.</font></div><div style="padding-left:4.5pt;text-indent:-22.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SPY003</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; a highly potent and selective investigational monoclonal antibody targeting the p19 subunit of IL-23, engineered with half-life extension technology and formulated at high concentration with the goal of maximizing efficacy and enabling infrequent, subcutaneous maintenance dosing.</font></div><div><font><br></font></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:35.03pt">In October 2024, preclinical data for SPY003 were presented for the first time at UEGW, demonstrating comparable potency to risankizumab, as well as a pharmacokinetic half-life of 30 days in NHPs, greater </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">than three-fold compared to risankizumab. These data also demonstrated that SPY003 exhibits high selectivity and affinity for IL-23 and potently inhibits downstream cellular signaling.</font></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:35.03pt">SPY003 remains on track to initiate a FIH trial in the first quarter of 2025, with healthy volunteer interim data expected in the second half of 2025.  </font></div><div style="padding-left:4.5pt;text-indent:-22.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Rational Combinations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; the Company plans to investigate combinations of our proprietary antibodies in nonclinical studies and clinical trials in order to evaluate whether combination therapy can potentially lead to best-in-class efficacy in IBD, with less frequent dosing.</font></div><div><font><br></font></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:36.3pt">In February 2025, new preclinical data for SPY120 were presented at the 20th Congress of the European Crohn's and Colitis Organisation, demonstrating that the combined inhibition of TL1A and &#945;4&#946;7 is superior to either monotherapy in mouse models of colitis and that coadministration of SPY001 and SPY002 demonstrated no drug effects on PK in NHPs. </font></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:35.03pt">In October 2024, preclinical data for SPY130 and SPY230 were presented at UEGW, demonstrating enhanced efficacy and pharmacodynamics with SPY003 in combination with SPY001 and with SPY002.  </font></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:35.03pt">The Company expects to initiate a Phase 2 clinical trial in 2025 that is intended to include each of its rational combinations, as well as all three of its lead monotherapy programs. </font></div><div style="margin-top:24pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Corporate Updates</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:58.5pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:30.53pt">In December 2024, Spyre was added to the Nasdaq Biotechnology Index.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:30.53pt">In November 2024, the Company raised $230 million in gross proceeds from a public offering of common stock with broad participation from both new and existing investors, extending cash runway into the second half of 2028.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:30.53pt">In October 2024, the Company announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as Chief Medical Officer. Dr. Sloan's 25+ years of experience in both large pharmaceutical and small biotech companies, featuring an extensive track record of program leadership in the field of Inflammation and Immunology, will be invaluable to guide the Company as it advances its potentially best-in-class IBD portfolio.   </font></div><div><font><br></font></div><div style="margin-top:12pt;padding-left:40.5pt;text-indent:-40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fourth Quarter 2024 Financial Results&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Position&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> As of December&#160;31, 2024, Spyre had cash, cash equivalents, and marketable securities of $603.1&#160;million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Net cash used in operating activities was $37.2&#160;million for the fourth quarter of 2024. In November 2024, the Company raised $230 million in gross proceeds, before deducting $14.2 million in underwriting discounts, commissions, and other offering expenses, from a public offering of common stock.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development (R&#38;D) expenses&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> R&#38;D expenses totaled $50.5&#160;million for the fourth quarter of 2024 and $33.7&#160;million for the fourth quarter of 2023. The increase was primarily driven by nonclinical and clinical development, as well as manufacturing expenses, for the Company's pipeline candidates.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General and Administrative (G&#38;A) expenses&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> G&#38;A expenses totaled $10.8&#160;million for the fourth quarter of 2024 and $14.1&#160;million for the fourth quarter of 2023. The decrease was driven by higher stock compensation expense related to the Spyre acquisition in the fourth quarter of 2023. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other income (expense)&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Other income totaled $5.0&#160;million for the fourth quarter of 2024 primarily driven by interest earned on the Company's cash and marketable securities. For the fourth quarter of 2023, other expense totaled $17.3&#160;million, primarily driven by an increase in the Company's CVR liability related to the increased likelihood of certain milestone payments related to pegzilarginase reimbursement in European markets, partially offset by interest earned on the Company's cash and marketable securities.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss totaled $56.3 million and $63.2 million for the fourth quarters of 2024 and 2023, respectively, which includes non-cash stock compensation expense of $9.2 million and $17.3 million for the fourth quarters of 2024 and 2023, respectively.</font></div><div style="margin-top:24pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Spyre Therapeutics</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes investigational extended half-life antibodies targeting &#945;4&#946;7, TL1A, and IL-23.</font></div><div><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For more information, please visit http&#58;&#47;&#47;spyre.com.</font></div><div style="margin-top:24pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Safe Harbor &#47; Forward Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains &#34;forward-looking&#34; statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical fact are forward-looking statements. These forward-looking statements include statements regarding the Company's future results of operations and financial position&#59; its business strategy, including the Company's ability to successfully develop best-in-class and&#47;or first-in-class therapeutics for IBD, RA, or other immune-mediated diseases that meaningfully improve both efficacy and convenience compared to today's standard of care&#59; the SPY001 Phase 1 trial final data readouts not being consistent with or being different than the interim Phase 1 results&#59; the sufficiency of the Company's funding to support the development of its assets, including expectations of cash runway extending into the second half of 2028&#59; the length of time that the Company believes its existing cash resources will fund its operations&#59; estimated market sizes and potential growth opportunities&#59; its nonclinical and future clinical development activities&#59; clinical trial designs and related regulatory feedback&#59; further clinical evaluation of therapeutic combinations&#59; the potential efficacy, tolerability, convenience, commercial viability and safety profile of its product candidates, including in combinations&#59; the planned dosing regimen for SPY001 and our other product candidates, including the potential for a Q6M dosing profile&#59; the potential therapeutic benefits and economic value of its product candidates as monotherapies or in combinations and their extended half-life&#59; the timing for initiation of nonclinical studies and clinical trials, including the commencement of FIH and Phase 2 trials&#59; and the planned expansion of SPY002 into RA, including timing thereof. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; the negatives of these terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the expected or potential impact of macroeconomic conditions, including U.S. elections inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in monetary policy, the prospect of a shutdown of the U.S. federal government, volatile market conditions, financial institution instability, as well as geopolitical instability, including the ongoing military conflict in Ukraine, conflict in Israel and surrounding areas, and geopolitical tensions in China on the Company's operations, the potential impacts of the BIOSECURE Act bill if passed into law and those risks described in the Company&#8217;s Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, as well as in other filings and reports that the Company makes from time to time with the Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for the Company&#8217;s management to predict all risks, nor can the Company assess the impact of all factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. The Company undertakes no obligation to update publicly any forward-looking statement for any reason after the date of this press release to conform these statements to actual results, to reflect changes in the Company&#8217;s expectations, or otherwise, except as required by law. You should read press release with the understanding that the Company&#8217;s actual results, levels of activity, performance, events, outcomes, and the timing of results and outcomes, and other circumstances may be materially different from what the Company expects.</font></div><div style="margin-top:24pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contact Information&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media Contact</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dan Budwick, 1AB</font></div><div><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">dan&#64;1abmedia.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor Contact</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Eric McIntyre</font></div><div><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">eric.mcintyre&#64;spyre.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6bf35f1a0c9f44d5aa5c1c90e163221e_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spyre Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in thousands, except share and per share amounts)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br>2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br>2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS </font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CURRENT ASSETS</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,423&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,893&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513,665&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,384&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,386&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,251&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.87pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">608,474&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,528&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Restricted cash</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other non-current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">TOTAL ASSETS</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">608,484&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,859&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CURRENT LIABILITIES</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">896&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CVR liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,080&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,390&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued and other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">27,711&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">13,108&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Related party accounts payable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">603&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">16,584&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.87pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">54,060&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">31,978&#160;</font></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-current CVR liability</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">36,620&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">41,310&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">TOTAL LIABILITIES</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,680&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,288&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commitments and Contingencies</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Series B non-voting convertible preferred stock, $0.0001 par value&#59; 150,000 shares authorized, issued, and outstanding as of December 31, 2023.</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,555&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Series A non-voting convertible preferred stock, $0.0001 par value&#59; 1,086,341 shares authorized as of December&#160;31, 2024 and December&#160;31, 2023&#59; 346,045 and 437,037 shares issued and outstanding as of December&#160;31, 2024 and December&#160;31, 2023, respectively.</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146,425&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,927&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Series B non-voting convertible preferred stock, $0.0001 par value&#59; 271,625 shares authorized and 16,667 shares issued and outstanding as of December&#160;31, 2024.</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,395&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Preferred stock, $0.0001 par value&#59; 8,642,034 shares and 8,763,659 shares authorized as of December&#160;31, 2024 and December&#160;31, 2023, respectively&#59; no shares issued and outstanding as of December&#160;31, 2024 and December&#160;31, 2023.</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Common stock, $0.0001 par value&#59; 400,000,000 shares authorized as of December&#160;31, 2024 and December&#160;31, 2023&#59; 60,257,023 shares and 36,057,109 shares issued and outstanding as of December&#160;31, 2024 and December&#160;31, 2023, respectively.</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,334,223&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">763,191&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(972,432)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(764,414)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TOTAL STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517,804&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,016&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">608,484&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,859&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i6bf35f1a0c9f44d5aa5c1c90e163221e_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spyre Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in thousands, except share and per share amounts)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Twelve Months Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Development fee and royalty</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">886&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">886&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and development </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:114%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,482&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,682&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162,790&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,504&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,771&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,072&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,776&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,946&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Acquired in-process research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,188&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Gain on sale of in-process research and development asset</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,840)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,449)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,253&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,914&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,566&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,189&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,253)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,914)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(208,566)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242,303)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other (expense) income&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,776&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,126&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,312&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,147&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of forward contract liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83,530)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other (expense) income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(818)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,392)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,713)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,130)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total other (expense) income </font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,958&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,266)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">599&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,513)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax expense</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,295)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63,180)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(207,967)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(338,816)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (expense) benefit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,296)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63,180)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(208,018)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(338,790)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss per share, basic and diluted, Series A Preferred Stock</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.28)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.17)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127.21)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(550.28)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted-average Series A non-voting convertible preferred stock outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346,045</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">860,495</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,387</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434,612</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss per share, basic and diluted, Series B Preferred Stock</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.28)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.18)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127.21)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(550.29)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted-average Series B non-voting convertible preferred stock outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,667</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,239</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,208</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,630</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss per share, basic and diluted, common</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.81)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.23)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.18)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.76)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted-average common shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,259,227</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,607,898</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,027,638</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,897,065</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Includes $6.1 million and $41.2 million in related party expenses for the three and twelve months ended December&#160;31, 2024, respectively, and $27.7 million and $48.5 million related party expenses for the three and twelve months ended December&#160;31, 2023, respectively.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>syre-20250227.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:54931160-13e1-4cff-902e-afae7a4c5b0d,g:a98c0da1-7b90-44ac-a2da-2ee51b9ca29c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:syre="http://spyre.com/20250227" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://spyre.com/20250227">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="syre-20250227_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="syre-20250227_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://spyre.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>syre-20250227_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:54931160-13e1-4cff-902e-afae7a4c5b0d,g:a98c0da1-7b90-44ac-a2da-2ee51b9ca29c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentPeriodEndDate_704f0f40-ae21-447b-8dda-3f05de307bfa_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_981df188-f59d-40a5-a7d9-dcfe7c24ff13_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_257b0134-8ba2-4410-ba76-7e4c43953d20_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c336fe6e-e510-4d72-8930-f749547916d3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f7c8de4f-3362-4f2f-9f40-481b15368f63_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5918f049-2a8e-46fc-b335-c000be087a15_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_59d7871f-da71-4458-a3e0-79f4a36324f9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0b3a7e4f-d269-4e28-bd3b-27b31a198294_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_efd30406-93eb-4947-9d87-9f36c12c26c3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_41b67f10-5fd6-4d42-9e53-730aff727f8d_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_56455d63-5389-4004-b846-4b0c7768c39d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e83ee70a-2dc9-435d-b0f1-80fb036276c8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0f08c986-7337-4500-bf27-a09eb13f7e2f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ddade581-c834-4751-aa75-bd48f7da32c0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_10b07c86-dc3e-4a6d-9ad5-0c2b607de43b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_367ff9f5-e600-489a-b0b4-3627ad4ac1fe_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_970cd6ee-b682-4dce-8bb5-5a10e0001e41_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_988ab57e-c76d-4fca-9f22-65c6cc41fa0d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fbd020c8-ba78-4516-b585-03efba10cce8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_61cf433a-8399-4ebd-b706-e43ffc1994c0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e30c3d59-10d2-4a65-8ef2-848ac66fc567_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_292912e5-e05a-4942-9771-543293cf7c9e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_96591fa8-d6f7-438b-be1e-e7e9db3e0275_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine3_41cffeb6-fb97-4423-b7e6-33b8db723253_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Three</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine3_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3" xlink:to="lab_dei_EntityAddressAddressLine3" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_73d14a5d-2f38-4bbc-97a6-f37191b58064_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>syre-20250227_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:54931160-13e1-4cff-902e-afae7a4c5b0d,g:a98c0da1-7b90-44ac-a2da-2ee51b9ca29c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://spyre.com/role/CoverPage" xlink:type="simple" xlink:href="syre-20250227.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://spyre.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_13f10027-4f66-4294-86ec-625b62af783e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_DocumentType_13f10027-4f66-4294-86ec-625b62af783e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fae56153-ae4a-4883-82b9-ec5c78797507" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_EntityRegistrantName_fae56153-ae4a-4883-82b9-ec5c78797507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ca53edf3-3b8f-4247-890a-fc5166e4f5ca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ca53edf3-3b8f-4247-890a-fc5166e4f5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_af180bca-ca81-4bb2-929b-8b27e5a7edb8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_EntityFileNumber_af180bca-ca81-4bb2-929b-8b27e5a7edb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4d9dd26c-f2c4-4d21-aefa-42ed26ea41e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_EntityTaxIdentificationNumber_4d9dd26c-f2c4-4d21-aefa-42ed26ea41e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f7157c6f-9d36-4019-9283-4fd1aea53fe6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_EntityAddressAddressLine1_f7157c6f-9d36-4019-9283-4fd1aea53fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_135893b4-5ed3-4454-a074-2f428ec9b743" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_EntityAddressAddressLine2_135893b4-5ed3-4454-a074-2f428ec9b743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine3_2ee1de30-6703-4722-99d9-55af46d366d0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_EntityAddressAddressLine3_2ee1de30-6703-4722-99d9-55af46d366d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_02d54337-d838-47d4-a00a-e17d64114917" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_EntityAddressCityOrTown_02d54337-d838-47d4-a00a-e17d64114917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c951ef54-8135-445e-b23b-434eb6d52e22" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_EntityAddressStateOrProvince_c951ef54-8135-445e-b23b-434eb6d52e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3e27092b-ef45-4c39-88c0-81ada441112f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_EntityAddressPostalZipCode_3e27092b-ef45-4c39-88c0-81ada441112f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7f00abc5-96c6-4c7c-bbdf-d8785f431943" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_CityAreaCode_7f00abc5-96c6-4c7c-bbdf-d8785f431943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bbcc9628-0868-4976-a440-77c925003b9b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_LocalPhoneNumber_bbcc9628-0868-4976-a440-77c925003b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a6d29706-f463-436e-ac09-787e55175013" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_WrittenCommunications_a6d29706-f463-436e-ac09-787e55175013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_2ba637e6-a973-4970-8368-0a892432698e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_SolicitingMaterial_2ba637e6-a973-4970-8368-0a892432698e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b47fcc0f-dc8a-4adf-9011-24d85f1462fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_PreCommencementTenderOffer_b47fcc0f-dc8a-4adf-9011-24d85f1462fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_12787ed2-6245-426e-9e51-cf1570bee5fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_12787ed2-6245-426e-9e51-cf1570bee5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_76a74f85-7bcb-4ed8-930e-c02d73754e89" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_Security12bTitle_76a74f85-7bcb-4ed8-930e-c02d73754e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a5df7f6d-6018-4dea-ad93-40770647f4a2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_TradingSymbol_a5df7f6d-6018-4dea-ad93-40770647f4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9479a53d-d3a9-43da-9fe0-a89430fde60c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_SecurityExchangeName_9479a53d-d3a9-43da-9fe0-a89430fde60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f6e9e5bf-0f36-4fa1-8969-e103c6a60c72" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_EntityEmergingGrowthCompany_f6e9e5bf-0f36-4fa1-8969-e103c6a60c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c3b74128-4c83-4b38-8191-d683c7fcff81" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_AmendmentFlag_c3b74128-4c83-4b38-8191-d683c7fcff81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4757405f-0efa-4830-94ff-66ef5187e1c1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_EntityCentralIndexKey_4757405f-0efa-4830-94ff-66ef5187e1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6ed5842d-6691-49bf-9483-439834096b91" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_66d37032-eb9e-4b3d-bbc4-94d9099821ef" xlink:to="loc_dei_DocumentPeriodEndDate_6ed5842d-6691-49bf-9483-439834096b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_759decb9-8f95-435a-a6a3-b0cf59a8cc37" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>spyre-logoxhorizontalxfulla.jpg
<TEXT>
begin 644 spyre-logoxhorizontalxfulla.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M5"47_]H # ,!  (1 Q$   "_P   #B?=S%9FG1>;V.ZD\0D<MSZQG3(
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M]._:"^'S7\=<QX#5H       $$FS+/6C]@8_LW>.<AKF[9L*ZFV;'9K\<Y
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M/V01<IJ%+_'_ %'\M E%0$D[$IIK*6@S[NF^PV)G_4*4FNH9<P&*'J=D[>#
M_=PQ@RPP"=/-,!M=51'.[2I<N8-CTPM-75S1K-!M,I,7W$A-9,J?=N>.ZGSY
MY4.=.F-PSXISK3FL;'J:7%""'"J?:DVG+#O8[J8BFBKBPW5%V.@\\EGI E90
M1-FA670P*'H*& #H ' Y*4<3=@<::?ZTUT_WH6+2EH$*2SC0,%VP8 ,H 8Y2
M482!0]!0P - )-A@OH8EW8'  .@ <#E0C$2)P,LVP23020N!H7DV%RLI?6)I
M=)M)TT+74 H$!K$\DHDNJ8%_L,.0*3:F IY@_0A6HVGS>(UB'<[:E%TVKLU5
MYW#U29O+>%*7%<,G%_$:Q%07&V_#3]!IMW[^Z__:  @! 0 !!0#J%Y=1VNAX
MV;HEB[FJ]X)DR2M*QQ7;E[N;<O\ !<WEW^C09G+\^4+ROM!QOW<&+1KC2Y@N
M;+_X)=^Z7 \[J.7Y\H7E?:#&*YT+[PL$ZH\>))A*YOF0,;%NZ^+S;MN.@GJW
M;=H]6[;M'JW;=H]6[;M'JW;=H]6[;M%@-Y[8O]MBR=9M*6XQJM>K=MVCU;MN
MT>K=MVCU;MNT>K=MVCU;MNT,?FR;-%92M%R%6>WT(EX]P[JM5H'ZL^S&+=N9
MUL2KI6"6:6>7;6&L-,Z 4S6>:LQO)8C!YH.R&J3TJA4X"EE%?5NV[1ZMVW:/
M5NV[1ZMVW:/5NV[1ZMVW: .;<MOF&MNYDK&I7U:2U5,7$W95.K-,:'L>MG-)
M8[J<JGJW;=H]6[;M'JW;=H]6[;M'JW;=H]6[;M'JW;=NIN7^X[E^?*%Y7V@Q
MB*_7EU7,$Y@'M<-5SJ.6Z_4OS9_WG].EU4ZC43?^%?*.GY*;=<_&#Z:FPT8
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M /6%AB!:5V  &DDF@ Y2<;OLEH9MB1I#QN2E?8&2CD Q9*P!4W<-1_U%PT*
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M3[;\Q\>GVWYCX]/MOS']9M?L\?Z"XL_@2>VF++[7#\XO!=?]/YF/UN+O%O-
MV]YT#1AA\C&PJI .B1QF3I4$**':KZQ<_P!W#\TN+O[;_A)ZP]E?1I+:2+1E
M85!'C&D$9@T(((P!;U;=%Q5H2<RM*;4;'64J*'RE(.G:I%W9W\_^;'1@F8_*
M<4;D^7J1O+R4].FWB3O/N",ER2UQ$HTZ2TR#CUR*-/7%*-7@2TM$:2YD8*JJ
M*EB=  Q]:N@'W],@[1M(C!H>R3D!IM-Y9'Y( PT\[*D**69F( 4 5)).0 &9
M)T8_=N[2R;AB;+2#,P\MQJ4>0IS'6;I$!;#[;!\ZOK+[SW<@3O!$I(( ';@#
MJ/QO04C8YUHI.S0K0Z<0[LL5VKN=PJC54ZR=2@5+'4 3JP+6S4->,!VLQ'2D
M;\.R@\E :#2:L2Q_H%K]GC_07%G\"3VTQ9?:X?G%X+K_ *?S,?K5ENZ05BGN
MHD;X+.H;_P!-<4&C$7=[<\C0.\7:2R+D]&+*J*VE>J68K0FJ@$#:!J;JXK_>
M/\;'I5QYQ_C8]*N/./\ &QZ5<><?XV/2KCSC_&QZ5<><?XV/2KCSC_&P99W9
MY3K8ECERFIQ=_;?\),7SH2'%G,01D01&U"#QX]*N/./\;'I5QYQ_C8]*N/./
M\;'I5QYQ_C8]*N/./\; NK&\G#@YAG9T8<3(Q*D>$5&H@YX@WPBA)7!61?R9
M%-& Y#UEU[)%<ZXN9& [:V*S(>(JP5N=&;V:<6*C(C"=WM^.?WNHI%(W]LHS
MV6/_ !5&L]<"I.W7:Q)WEW"A^J$EIXE'R9.9D0#^SUNOD:1T*A%@@5GF=@JJ
MH)+$F@  S))R &G WIO(!M_RIGK$*G2BZBYT.X^"O1J7+N0$ J2<@ -))XL'
M<NYG9=QQMTF&7;L#D3K[-2*J#UCTF&2A<6'VV#YU>"WCMII8XSN]#17917MI
MQ6@(SR&?)CTJX\X_QL>E7'G'^-CTJX\X_P ;'I5QYQ_C8J+JXK_>/\;"=W-^
M2M/#,"(I'-71P"=EF.;*P! VB6#4 -#EB\A@ $$C+*HXNU4,PIJ&V6H.*F+O
M>T@J;:%47D:8M4CE"QLO@8\>*G1B6#=T\D&Y$<K&L9*%U!IMR$48EM(4G944
M%*@L?2KCSC_&QZ5<><?XV/2KCSC_ !L>E7'G'^-CTJX\X_QL>E7'G'^-CTJX
M\X_QO6;7[/'^@N+/X$GMIBR^UP_.+P77_3^9C]:L]Y/78M[F*0T_)1PS#V0"
M,"1""C $$:"#F".0XBWWN51)?11]G)'4 N@)960D@%E+,"":L"*9K0E3NO>%
M0?\ ]>8_A"4/L8^Z]X_^--\3'W7O'_QIOB8^Z]X_^--\3'W7O'_QIOB8 WC;
M7%N3_P 2-T_2 X;O[;_A)B_^Q3_--ZLE@0&NY2.4405YP1[&-Y%C0?4Y![)6
M@_">!98F*R*000:$$9@@C,$',$:,+N;?#A=_(O18T G4#2-7: ===8&VN6T%
MH<P<3[_LT/;R?)H0-B':Z_9BF6UJ_)4E5H">!N[^X)#^ZU)$TJGY8_D*?^$-
M9_M#HZ J_!8?;8/G5X+?^'1_/3^JW:L8)87:'+B4[3'V%!)Y!P2?9XO:.-Y?
MWD/Z,F)%458QL .6AQ]V7OFF\6/NR]\TWBQ]V7OFF\6/NR]\TWBQ]V7OFF\6
M/NR]\TWBQ]V7OFF\6/NR]\TWB]9M?L\?Z"XL_@2>VF++[7#\XO!=?]/YF/UN
M/NSON0)>1@+!(QHKIY,98Y!UT)6@9:*.D.EZIH+A%DA84*L RD<1!J"/#B3?
M_=E"B1C:E@&8"Z6>+6-G2R:-FI6@&R<7?VW_  DQ=6<%.VEMI46N0VF1E%3J
M%3CY.W\Z/%CY.W\Z/%CY.W\Z/%CY.W\Z/%CY.W\Z/%A5WI)!;V8/2*MVCD<2
MJ !7E9@!IH=&(=U;O78M($V5&OC))ULQ)9CK8DX_=*G_ #=\X4#6(T(=V\!(
M5.7:/$>%+FV=H[B-@RLI(96!J"",P0<?4+\A=_PI5A2@E04':+J!S&VN5":J
M-DT7$O=;<;E8U+)<R#(D@T:%3I"@U$A\H]$'9VMKAL/ML'SJ\$.\-TK$ULEF
MD9VG"G:$DK'(ZJ.,\?)V_G1XL?)V_G1XL?)V_G1XL?)V_G1XL=2W\Z/%@[VW
MG(DV^"I5=BNQ$#DVR6 +.1D6HM%)4 U)P7<@(!4DY  :23Q8N]ZQ&MN\E(_[
MM $0TU550QY2<;R_O(?T9/Z%:_9X_P!!<6?P)/;3%E]KA^<7@NO^G\S'ZX+>
MVNC);+D$E D  T ,W3 &B@8"FK(8ZMEYMOI,=6R\VWTF.K9>;;Z3'5LO-M])
MCJV7FV^DQ^Z-ZQ)!O4J60I7LY-D590&)96 JU-I@0&S! !H<P<7N[(1LVZ2[
M2#4$D D4#D4,%]CCQ=_;?\)/6&>_E5KW9JD"D&1CJJ/(4_EM0<530%]Z[P-&
M;)$'5C05V47P5J3I9B2=/J&^Q2?I1\&]/XC<_//ZBP^VP?.KZPTTS*D2*2S$
M@  "I))R  S).0&'[O\ =MR;1P5FF&6V-<<>O8.AV--H=%>B26QO+^\A_1DP
M\B]94)'A )QU;+S;?28ZMEYMOI,=6R\VWTF.K9>;;Z3'5LO-M])CJV7FV^DQ
MU;+S;?28ZMEYMOI/6;>6#2D:QL-:L@ (/AR8<A&+/X$GMIBR^UP_.+BIT8N;
MVVS@9@%/&$54VO VS4<A_H4%[ K"SM"9)'U#HL%6NBKDTIIV=HZ >"\[,U""
M)3X1$E>8FAY0<7?VW_"3%Y<0,5FCM964C2&6-B".4$5Q]XW/./%C[QN><>+'
MWC<\X\6/O&YYQXL?>-SSCQ8[.;>5WL$4(61DJ.([&S7V<%Y"6<FI)-23QDG2
M?4M]BD_2CX-Z?Q&Y^>?U%A]M@^=7@@M-TW<L%LUBCE5(H6,LP)T'.B@>QC[Q
MN><>+'WC<\X\6/O&YYQXL?>-SSCQ8FW1OB4R;UA.VC-3:>,G,<IC;3[UE_).
M"K %2,QB6TB!_=TOZR$^\8YKX4:J\= K'K<&\-VL?UCQQ2*.1"ZO\XG@]G!C
M?JL"#X#EB7=EZK *Q[-Z92)7HNIT&HT@=5JJ<Q_0!:SM2QN2%-="OY#<F?1;
M1D:GJC%G\"3VTQ9?:X?G%Q^[K=J7ER"#32L>AC_6ZHY-K6/6]WVMTBR6TEW&
MK*PJ&!85!&L''W99>:7Q8^[++S2^+'W99>:7Q8^[++S2^+'W99>:7Q8^[++S
M2^+'W99>:7Q8%KN^&*"V&A8U"+7CHH J=9TG$N];TCHBB)6ADD/51?"=)H=E
M06.0.)=X7;;5S-(SL>-F))\ J<AJ&6+O[;_A)B_^Q3_--ZXWV*3]*/@WI_$;
MGYY_46'VV#YU>"W_ (='\]/ZF#?%I\K"X)&IE.3H>1E)7DK49@8AWE9MM6L\
M:NIY&%:'B(T$:B",.UNNUO2UK)%09M0=.,?#49#6ZIP0;X@!81M1UK3;C;)U
M]D9BNA@#JQ%O+=SB2TE4,I'X01J93DRG,$$'/'U?><$-Q!6NS(BN >,!@:'E
M&>/NRR\TOBQ]V67FE\6/NRR\TOBQ]V67FE\6/NRR\TOBQ]V67FE\6/NRR\TO
MB]71 2>05QU'YCCJ/S'%E'<U^NVZ.CU!JPZ&PV>L@9\H)UC%K=3&D,=Q&['3
M15<$FG@&)-X3(XVST10]%1U5&6H:>,U.O'4?F.-ID8+R@^LV>\[K:^K07".V
MR*MLJP)H"14^R,=6]\VOTF.K>^;7Z3'5O?-K])CJWOFU^DQU;WS:_28ZM[YM
M?I,=6]\VOTF"-S64[S4R,Q5%!XZ(TA8<FTOA&/KN]Y2[#)5&2(.)%T"NLYLU
M!M$\%Q9;U$YFEN-L=F@84V%7,EESJ#JQ=64*W?;36\B+6-0-IT914]H<JG/U
MP[SWF)#;&W=.@H8U9D(R)7+HG7CJWOFU^DQ>[QM]KZO<7<TBU%#LO(S+45-#
M0BHJ<]?J+6]FKV,-Q&[4S-$=6-!EG099XZM[YM?I,1;QW6)1;I:+&=M0IVA)
M*QH S94<9UTUR]5+NC?8F:T#[<)10Q7:KMJ066BUHPIK9JZ1CJWOFU^DQ/>[
M@$B[NF;;"NH4HS9NH 9AL[52NB@.S3*IP9=U2#L'-7B>K1ORE:@AM6TI#4RK
M3+ &];.XBFU]D4D7P](QL!KI1CJSQU;WS:_28ZM[YM?I,=6]\VOTF.K>^;7Z
M3'5O?-K])CJWOFU^DQU;WS:_2>I"("7)H ,R3R#"W&]R;>VT[ ^4;PUR3V:M
MQJ-.!;V$2QQZZ:3RLQS8\I.#<7<BQP+I9C0?[SJ&DZL-;;B7971VK#/PHIT>
M%L_>@YX:>X=GF8U+,223RD\"P2GZQ8CR&.:CWC9D> U7B TXK92?KP*F-LG'
ML:QRJ2.6N"C@,A%""*@@ZB-8PUQN<B"XT[!^3/@UI[%5U4&G!MK^)HY>701Q
MJ1DPY02/].B5%[&Q/]HX-"/>#2_L4746& UNFW=TSD?-O8U*.117C)Q4Y 8:
MWW;2YO!E4']6IY6'7\"Y>^!RQV^\)&=M0T*O(JC(>V=9.%@MD:29CDJ@DGV!
MA]\=XF%5%$@4YLYZJNXT9YL$J=D$[65,2;O9^PWJM7C;2KKK1EKI4Y@KG0FH
M(7'9W\9"$]%QFC>!OQ&C<8P)869)5-002"#Q@C,'"VV^U,L6CM%'3'PER##E
M%&^$<"YL9%E@.M3^ C2#Q@@$:Q@VU]&LD)U$:.4'2#R@@X:YW(3+#I[-NN/@
MG(,.0T;4-HX,4JE9%-""""#Q$','_3/8;OB9R-)T*OPF.0\&DZ@<+<;RI<W@
MSH1^K4\BGK^%LM'1!Q09 8*W#[=W3*-*%N3:U*.4YTT X,;MV5D?[-":$>^.
ME_9HO$HX%N+VMM9'.K#IL/>KJ!_*:FH@,,=E81A6(S8YNWPFT^P**-0&/J4!
MK96Q*Y:&?RFY:=4> D&C8COK8TGB8,/Q@\A%01K!(PEQLK):3)FK ,*Z&4@Y
M54U!Y148:YW$VRVGLF.7]1CH\#9>^ RP;:\C:.==*L*'P\H.HC(ZL"YL)6CD
MUTT'D8:&'(0<+;;X @N=&V/DV/+K3V:KI)8:,!T(*$5!&8(Y#BEXE+BE!(N3
MCV=8Y&!'%0YX:=!V]@/+49J/?KF5\(JO&1H]8.\=T0I):B0I4R(IVE )%&8'
M6,\>C1^>B^-@;NWN@CNC&'H&5ALL2 :J2-(.7!_]I:)?W-0';VTK0R"(="NU
MUS31RZ,1;KW>H>\F)"@D*"0"QS) &0.DX.[=ZH$NPH8@,&%&T9J2. ;RW5"C
MVA8K4R(IJNG)F!QZ-'YZ+XW (TZS$ >$Y8]&C\]%\;"C?-LT2.:*U59&/$'0
MLM:9[)(:F=.&5-RQ"0PA2]65 -JNSFQ J=DY<AQ+NZ]78NX9"CBH-"IH:$9$
M<1&1&8X(MVV*AKN9ME02 "?": >SCT:/ST7QL"TWS \$S"JUH58<:LI*M370
MFFNG ]IN>-9)XX]M@65*+4+6K$ YD98]&C\]%\;#[KWH@2\0*2 P848!AFI(
MT$:^!>\TT2C<[A2'VT)HS;(Z-=K3R8&[=U('NRI8 L%%%TYL0,2[KW@H2\A(
M# $, 2 PS!(.1&@\$-_:V\;6T\2R(>UC%5=0RFA:HJ",CF,>C1^>B^-B:PN@
M%N8)6C<5!HR,585&1H0<QD>"*3?,2QK,6"4='J5H3U2::1IX*#,G N%M1#&P
MJ.U=48CX%2P_K '"IOFW>%7/1:H9&Y ZDK6F=*[0UC@"("7)H ,R2=  X\?6
MQ:J"5KV9D024^"6H#[TD-J(KEA[:Y1H[A&*LK AE(R((.8(.D'U$=I;C:GD8
M*HY3^+C.H9XBW?!H1<S^4QS9CX3S"@U8^L;PE6./572QXE49L? /#EAK?= -
MO:G+;/RC<U0GL5;WPT8+N27)J2<R3RG'^42EO7.1LD'L^4>103QT&>!,P[>^
M'EN-!]XN87PYM[[@ELK"02;T92HV<Q&3D26T;0SHHJ0U-H <+V6\"PL)"""!
M78?020,]EAIH"00*#,X6XMG62!A4,I!!]D8[#>$2NNHZ&4\:L,Q[1U@C#7&[
M*W-I^2!^L4?!'7\*Y^]&G%#D1@+;OMVE<XWJ5Y::U/*/9!P(E;L;X_V;G,GW
MC9!_8HVLJ!P&:!:6-Q5EIH5O+3DH34:MD@#0?5FQW1=O#:ERVR%0C:( )Z2D
MY@#7C=U_NRX:&\F>,.P"DL#"S')E(S85R P+[>\QFN@@7:(4'9!) Z( R).K
M@BW5NU0][+&NR"0H.S=ASFQ '14G,\F+/>F\($2SA=BQ$L;$ HZC(,2<R- Q
M)]GB]H\$Z[FK^]BUQV5"H/:9;.;]$9_E9<>)-Y;RDDCLH@"[;5FU 2%&2EF.
M9 R!X(O[Q?TABS_^E]I_:]ML=E_RNSKVG]>FSRUU88=[2AW[2.O5KVG;#8IL
M]';$77V<J;=,N$;_ -Y#9^MW*,=1V&D6%/" NU+3B)S&J/>T8I#>PBI_YD5$
M;_T=F>4UX-W?:1[1PL7==;T[M^KH?U5OVJ;>T^U5NS<5ILU%=%,L\65QOI53
M?7:0$@4RE:)NU44T#K$@5%0,S0'@N_L7^*F+IMU&3]V&YE['IV8_5;;=GDS;
M0Z%.MTN//$ESOF0R;QKL.QV:U3HTZ("Y4IEIY>"W_NX/GAB/[/+[0QO#^\3Y
MI.#=FY6O'.Z^VAA[/92G9BBA:[&U39%*UKRXAL]SW3P6S62.5"H:L99E)Z2D
MZ%4::98DO+IB]S-(SNV729B68Y4&9).0 X-V_P!Y-^C'P3[UNE#I8HA0',"6
M0MLM37LA'(XFV6%"!B:/<]PUMNR*1EC"!:L%--MV()):E=FNRH(%"06,VXN\
MD$EQOAP0LBA%6HH8Y6T;+JVD(E&4',;1'!N^>_*K;+<"I;JAB"$)KD*.5-3D
MNFHI7"[]W(#=]WUC :W4 TH.EM*!MFIZ0D0G9T, HZ4N]=Y;'UR4C:V5"@4
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MO>)%DDMY-H*20#D10D9Z\#>MS$D,@B6/94DBBEC6ISKTN&6^MH4F>6+LR&)
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MB*PL8VEO9Y%CC115G=V"HJC668@ <9QW5[N1[+;P-O=RW4@_M+B1K;;-=:H
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M4XZIQU3^#%"2IY?'BHT<.TY 7%%VF_VY?%CJG'5..J<=4XZIQU3CJGUG<O\
M";/]GCQW?^SW?Z<&.[G\>W?^UQ<&^_\ L_V"U];,*']6-/*?%ZR/"?;POP?Q
MGU@,IHPQG\H-/CP9HNKK'%RCDX^ 0RG+4?Q>+A+,:*,;*Y1#1R\IQ0:<;;YR
MG\'^VO#?!/M>L[#G]4?P<OCX"[=4#&TW5U#B_H.Y?X39_L\>.[_V>[_3@QW<
M_CV[_P!KBX-]_P#9_L%KZTSC2%/M<!ED%0#0#\>.J.;'5'-CJCFQU1S8ZHYL
M=4<V.J.;%!D,+\'\9POPA[>.J.;'5'-CJCFQU1S8ZHYL;+*,&,Z-7@P!J;+_
M &]G@,L7R>L<7N>UP"&4]+4>/D/+[?AQ4Z,;"?) \_+XN#M)/E3^#W>!O@GV
MN D@$[9]H8ZHYL=4<V.J.;'5'-CJCFP9HQ0C2.!2=(RYO<PL8UGVO]_ "X!D
MUUU>#'5'-CJCFQU1S8ZHYL=4<V.J.;'5'-ZSN7^$V?[/'CN_]GN_TX,=W/X]
MN_\ :XN#??\ V?[!:^M,FLJ1BATX,<F2DU!QUTYQCKISCQXZZ<X\>.NG./'C
MKISCQXZ# ^ UX5^#^,X7X0]OU?\ 5'X\)\(<%#HQVD?R1_![G (F.0T\OAX.
MUE'3U#B]WVN%O@GVN _#/M#U3U_)/ /"<)X#^+ \..NO/CKKSXZZ\^.NO/CK
MKSXZZ\^.NO/CKKS^L[E_A-G^SQX[O_9[O].#'=S^/;O_ &N+@WW_ -G^P6OK
M9FC%5.D<7+ZNHR.!%,=.@_B/CX%^#^,X5CH!!_#C2>;&D\V-)YL:3S8TGFQT
M 2W-@N_6.-OR5'X3PT.8.-I?DC^#D\7 )Y1GI _'XO4-\$^UP%)*UVJZ.08T
MGFQI/-C2>;&D\V-)YL;""D?X3P*AT@9^$YX3P'\7]"W+_";/]GCQW?\ L]W^
MG!CNY_'MW_M<7!OO_L_V"U]<J5HW)ECRN?W,>5S^YCRN?W,>5S^YCRN?W,=H
MA)3772.!7.FF?A&6%^#^,^L=$='CU8")_O/J/ZP_'P)\ >T/4-\$^UZQ0:<"
M6;K:AQ<IX$\!_%@#'E<_N8\KG]S'E<_N8\KG]S'E<_N8\KG]S'E<_N8\KG]S
MUG=5]NTT:VM8[69*@M'-;QK&RM3\H!9$XXW0T!-,=W_L]W^G!CNY_'MW_M<6
M"[D!0*DG( #6<;W[Q[H).[)IHTC;\M;>"*W[0:.C)V7:*#F%8 YU_H14]9LA
MP+7E]O"_!_&<*#H+#V\=08Z@QU!CJ#'4&*A%YL4&CU/]8?CX$^ /:'J&^"?:
MX"TB@G:_$,=08Z@QU!CJ# DC%$.7@/N\ 8]<9'_;EX$?4"1S_P"[%<!U]GD/
M] &Y=Z2[/=G>[+%)M&BQ3UI!-GDHJ>RD-0-AP[$]DHQW?^SW?Z<&.[G\>W?^
MUQ8'='=4FSW@WQ&RL0>E%:=65N,&8UA3C':D$%!ZV[+D0IQUVY\==N?'7;GQ
MUVY\==N?'7;GQUVY\;3DD\N B^SR# 1>J!3"_!_&<+\(>WZY_6'X^!/@#VAZ
MAO@GVN _#/M#U)C;01@HW6!QGU&R/XCP&,Z_;P4<488JA(/)CKMSXZ[<^.NW
M/CKMSXZ[<^.NW/CKMS^K*V\;R,-.RI:GAH#CT:?S;^+'HT_FW\6.[MKOD2#O
M)NJ"XMYRZL#(M8.PF)89M(BD/G4R(S$ ,N-S;ZWBQ3=]GO:TGE8 L5CBN(Y'
M( J315)H!4Z!B\[U[PM[@&XD_5)L.1% N442Y4Z*4VB  [EGI5CCT:?S;^+!
MDE@F6,:248 >$D4]99%TD$8\GG]S'D\_N8\GG]S'D\_N8\GG]S'D\_N8\GG]
MS'ZQ@!R9^W3&S&*>V> ,E* 4SPK'9H"#I]SUS82E:USQY//[F%0Z0H',/4,H
MTD$8\GG]S!1Z5+5R\ ]4)(Z;6NOX,>3S^Y@++3;'!1QGQZ\=!@1RY>/'D\_N
M8\GG]S'D\_N8\GG]S'D\_N8\GG]S'D\_N>I6"W5GG=@%5069B<@ !4DDY #,
MXCWMW^:3=>YS0BW%/KD@]\""MN#[\-+D08ER; W3W6LX;2T%-K9%7D(\J60U
M>1N5V-- H,L2;WW]=0VF[8NM)*X1170*G2QT*HJS')03B3<_\L8C%":J;Z9.
MF=5;>!LD%,P\P+4/R*, V)-Y[WGEN=XS-M/)*Q=V/&S,23Q#B% ,AP1[MO6.
M].[*T'83.>TC7B@F(9D U(P>,#)54G:P'[NW0&\@FU):RT2XCXR4J0ZC*LD1
M=!4 L":8>VN422WD4JR, RLI%"K*:@@C(@BA&G$F]OY?O'NS>QJQMFK]4D/$
ME*M;DG\D/%Y(C0=('<_>FSFL[X5(#BJN :;4<BDI(E<MI&9:Y5K4?Z=2]MXO
MJ'=MB";N=2%9:T/81Y/.=-"NS%4;+2J:56;=,'UC?NS1KN>CS&ND1Y;,*ZJ1
M@$B@=G(K@NY"HHJ2<@ -))U 8DW5W.$>]]_K4%PW^3B/OI%-9R,NC"=DY@S*
MPIC]Y]ZKR2YD%=A.K%$#Y,42T1!QD#::@+,QSQ'NO<]O-=;QE-$BB1G=CIR5
M02:#,G0 "30#$_\ ,#^;4@$D2@6^[8G&U-<."(HIYT.0VJM(EN681*SB4%2N
M+ONI-.=V]^80T]K,*M%<19"2"6(L.E$U'1XB'[-W+*ZQ 8^J]Z+1H[=F(CN$
MJ]O+3\B4 "M,]APD@&;(,1WUA+)!>Q,&22-F1T8:&5U(92-1!!Q'NC^9,;7E
MCDHO(@!<(- [6,468#6R[$@%21*QIA-\]VKN&\W:^AXVK0TKLNIHT;BN:.JN
MNM1A]S=YK2&\W<_DR"I4_E(PHT;C4Z,K#4<2;W_EQ(U]N\58VDA N$&D]DYH
MDX&I3L2TH!VK&N'L[Z*2&\B8JZ2*4=&&E65@&4C6" 1_IG]W=U;*2Y<$;<G5
MAB!URRM1$RJ0"=IJ416.6(][=\"F]^\"T8(5/U2)A^3&V<Y!KTYALG(B%&%2
M$0!444 &0 &@ :@,-!O2?ZSOZG1LX"&FS&1D-=F%3D:R$,1FB/2F'M+F7ZCW
M<;1:0,P1AJ[9\FG/'M;,=158U.*#3B/>O>+:W/W;:C!I%_S,RG_A0FA12-$D
MVR*%61)5./J7=:T2*1A229NG<2Z#^LE(VB*BH1=F-3U47![M[LDVN[NYV:,4
M/1EN=$TF61"$=C&<Z;,C*=F3%IWDW.^QO*SG61#J-.LC4I5'4E''E(Q&O%OO
M<0PW6XMXVX+PRJLB@]62&16&R6BD#(<J57:7*AQ)O?\ EC((9\V-C,Y[,\D$
MS$E#Q),2M3\JB@#$FZ-_VLUIO.,]*.52C4U$5ZRGR66JL,U)&>%WOW6O)K2\
M%-K9-4D \F6,U21<ST74@',4-#B/=/?]4W7O@T47 K]4D;15B:M;$Y=<M$*$
MM*F2X6>W97@=0592&5@<P014$$9@C(X*]X+;8WH%I'=0T2X2F@;=")%'Y$@=
M14[(4YXDWC;(=Y]V%J?K$"G;C7CN(>DT=!I=2\0RK(I(7UC8D-&IQ'&D\QQM
MQFJUX.PK^L\')7!=^J,;:9KP;#FC> XTGF/!7&D\QQ^K->$&0TK@.O5(X"[=
M48TGF.-J,U' &D- 3C2>8XVTS4\'8@_K/!C;?)<!TZIX"K$[0--!QI/,<!EZ
MI%> B,UIR<--JIY,5C->'9VO9H:8J,P?46VXMTQF7>5W,L4:\;.:"IU*-+-H
M502<ABS[K;M *6\8[1Z4,LS9RRMRN]: ]5=E!DHP=[=ZKR&TM,]D,:O(1GLQ
M1K5Y&Y$4T&9H 3B3=/<-'W5N5JJ9VH;R0<A!*VX(U1EI 143+4KAI[AF>=V)
M9F)9F)S))-223F2<S@?N&V[/= :DEW-5+=*:0&H3*X_(B#L"1M;*G:$>\)4&
M\^\RT/UF=12-AKMX:LL6>AR7E&J0 TX+WNYW7NUNN^LL;1*82'2U9NBSR2CH
M"6,;6Q&NVZRA>T517%3IX+GNYWLDE7NM=N)$D52_U>?)69E7I=E(@&WL*[!H
MT*I1G.(]Z[FN(;K=LRU26)U=&'(RDC(Y$:0000"",?NOO59QW,0!V'ZLL1/E
M12K1T.0) .RU '5ERQ)O7N87WON$5/9A?\Y$O+&HI.!^5"-LZX0 6P4<$.#0
M@Y$$:01J(PL.Z9_K&XMHEK.<EH3728\PT+G3M1D G-U<982R@E^H=Y6TVD[
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M+>.O#]8J=KB]BF#&30''9@U%>#M"Q!ICK'%,4PVR2=JGX*^/ F4E7Y. QDD
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M7J9X^M_RYN-XFPD;.WNXE5HM)Z$R2OVBZ@KHKKE5Y*DC_2O_V@ ( 0$!!C\
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M-D.:(( B;_[7/<J-:BN5$4O'V!D3\KVB<:::7(XXRBI(AV'(MS!295Q^6=V
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MZG34%MJM8VN1SI0J;%TL-QW359ZD=D2&%7(0X_'KMK^>XWL9=+8\OZRNCO\
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M,)SF/1>EVG!?+7(_#VL)']C/H.-=GH,9:3('K$*ZNL)6?GP"6-:1[45\8_K
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8SM8E%9>3Q(\T64:*=RJC01D:UK_^=?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45997824749712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Feb. 27, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SPYRE THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4312787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">221 Crescent Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-5940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 Par Value Per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYRE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001636282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 27,  2025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJC9#QW?>;CR)56+L#7<T6+,5#[GYO XT7+F52BPR+G.A)-%\.73&_LTM[=J
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M]R]/$\[ S^P+\'RIE'F[L!\ JN\WH[\ 4$L#!!0    ( /. 6UJ?H!OPL0(
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #S@%M:!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /.
M6UJ"&R-D[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( /. 6UJ97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ \X!;6@3N-%9]
M!   RQ$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( /. 6UJ?H!OPL0(  .(,   -              "
M < ,  !X;"]S='EL97,N>&UL4$L! A0#%     @ \X!;6I>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  !@4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="syre-20250227.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://spyre.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="syre-20250227.htm">syre-20250227.htm</File>
    <File>syre-20250227.xsd</File>
    <File>syre-20250227_lab.xml</File>
    <File>syre-20250227_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "syre-20250227.htm": {
   "nsprefix": "syre",
   "nsuri": "http://spyre.com/20250227",
   "dts": {
    "inline": {
     "local": [
      "syre-20250227.htm"
     ]
    },
    "schema": {
     "local": [
      "syre-20250227.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "syre-20250227_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syre-20250227_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://spyre.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20250227.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "syre-20250227.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Three",
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://spyre.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001636282-25-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001636282-25-000022-xbrl.zip
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M@@[8O[C,&%TH<J9 "*4_\O@4U0DP; BZVF.NC 2J"$6FB[?O"F"(="\\:IH
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M.0%Y]9G9[*S<%G+%/JLJ0%[0V4 )Y2JD<)]6XX,EUMZ6VAKI'VYNQXP<+RL
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M-S4I.DE31^#<Q<,D&>5N(XJJ) $MGN9C] V ,,9J7:'B)&E1#@7C\,%.P%W
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M#:;P*?487+]:"BF6^DBJACNE1%:5FB=DN )4Y;-"- >S7>[-O6&:ZR)%B)/
MTW0G8RHUM?0OUOAJGN@99GQ9VU,2M6OA,6K*NC6W"J_=!-C07;<ZU7O7H#_-
MD_3C*9\O?H0;>/&SPLGEXE?ICE[\'"TO-IE?_!RA*R4'+'T#EMF53KSXL0*X
MBY^J)*SEAR;>TH<WJSZ,)JL^!;'Z2RQ/ 9FQM&Y2O-FGR#-?C"GND6(8##.)
M<)KVEP,68=T"W$B=.U4K=4H3A5T_9WCF3A&AF$R$5FO ,P(D(;8UP:B;:K%7
MRD'#PUPYFM\"/@Q\F0>L>#PA X<GZ+<@%0V:TJ8;>GCJ'(4B59&^4>OPZATP
M#*D7)4-DLVH0XB=TS 8D#V7T%4B5,R+=WV!VD^E,Y_&5]W96RH @-M-F &&X
M0J53[+>:Z;"LNV%I'(*ZJC0&A8(<6O+]PKF"JR (<$,HHZR#,,;R0J5]Q_K(
M(7M(Y 4W6###2/UB7QR2-@/[(/ICE; /FE+E\<\"3SJZ?RU(/X4Y<-Z<19,D
M5L,4 /E(N/2P,0"TT%=G.M<!3A<LD3;IQ47F0!4<AEC&B7;9L=. -GJ%(Z&Q
M"&:41.WH&[*+RD0/_'& OT_Q6UP%/'($ZZ"(Z)>O(2)^H_3A111RH1-(DI!:
M&=-)+49FU?8L/5M76!*ISL!]X<L1TQS9& NF3#$_<V3>7GR\.C_[<GE.CLH0
MX9$<L1E".5>I<H_?:+V/T0220H0F3BB'>8U,UOZ\;YG@XJ;Y$X"7TS?+P!1_
M1G_(;#5^-]BI[R>43['TY:\EFN/)-5EVL,Q DA0,J;N6(."4?Q4Z)TQAQ$#]
MS$I+"YX:#G3^30D=#J"/E)OL-_#H47[*I]J*H$H\.8.O51A(Q.K%,"JL,I,N
MK)C&5"G7US(,M!SB%9ACI@BH.JLL3S5M"HIZ$)RG2&*H>^',,2/RE/M\K.PV
MQN*5@2+UJ76%CT7EO,0A NFZPW*N!TCEPN_4H$I=GSEJ^N$$2>A!NELBC*5N
M,73M>I8HCO9!#6; '+%,!DL1\#"UT*H=>S63J\+0/H?J3$!W: IR/UZWC?9O
MLQ^8RH3/0?93=H*'*C<W<ZLTI[&L.E6PM?P0;> (1LG02:;HQ*$C@?D(B=XD
M*UQWF@\R$9N"J>;U"^LG,+""!'2I"P(6B3)!<FA"ZAR8Y\E\ ][B_-?'(ZL:
MO%8!#OP9)$Q!/9*5$#F>S%3L?RU"B-*=GCK5)2R&,2:-I58ZQYG.++GFH:#>
MZ)N($T$4-$P!EN&+LI9T,#TS9F/0_APK*_/'E8-&!GCSU[HP27O!8$9!Q5(<
M%0,H(.%K]]XVLTT3(KDS00+0UJ$]6>Y]1;E&,9D//V#!T$NC>*"FU!LC=!81
M[=!;E)%R*S$-BDC$2)!5P(2GKR]84A9X?!#XZGU*JF=&O@!$@27-8:C7*A )
MBJ!IE84H,CD/=]U(C"V*;]2LGN,T_DYDJ)K<@K5OLH)<8NAI8;:9-57O@$C?
M';%HC;-)+$[_#M8;FO%&YE,8F=^I'4E$PX4W?I2O4WBA+#&HC8>BJ&;S,!FI
MV)M%**%K<*H:H\>7I*'MOLA/'DII%Q4["\9D:\[TI'>L=-\!('J;N#?2^6HP
M\_3MAM/I=&W'?(+IN!PXUVV?F'Q(X6<\&:HH%R]T141%&'D>@COYFW/AQ_-P
M^<43S\M%N,MI3AU)<R%^9L=\%8=?[L8OKVV_VAEDVR #;MM7Q7V6&*WZ ![9
M90!V9QW[6_=\HZIZ9]CMO5HK,''8R2 \NB']6_V6T2M\R^CRT6[5YG[TQ>>)
M*ZF=-.&?((GPM0@9M(DFB%7I] 8S-M5?4\HB_W$+%:OSS=+MAQTB&K!&C\\B
M<9S^<@(.X<SC\V/ITTSIION\11BV1;.EMD8,^R%VTR?KKYOTU4^QN_Q=SVP.
M[/5?MYKFVN]N&]:TFJW^^EMO&_;V[]JM[M-,UMYHV)^(OHK&P,8(<-^_7]FO
M<M5&]4G'+6:2&*3CW7*I-?N&%R^KI26V![/':<?1W_#M3;KNU38-U+*8/Y9M
M@+N7=9@4L$L4N$,8\*!5O6.NH>?I.$*,1B>[6_C@KH63$CF]NCK_?,4VX/;:
M)6J51QH1M2K:"X;3/=E"0.XDX$/&V'*&6_-Z1/^[C==8Q/ALG%Y.96RC*?]R
M>7G^X3-3'+\7PQ?6>2^6//48C[11&?WL--O5XV.:[+Y8 ;G(TFU6W&(;"JW"
M(L^T7M)0WS]H7<7UA#CJ[A?4'QAMRUZH"+['VE(IW6*-CZF :_&JIGB9_;[1
M'^Q0OA[)?%97 _^VJLIHK4&UMEOYRJU2$='JF+;1[7:V%*U;V/M4JFM3D'%
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M7:NS2B."%C*[1K?[$%WV$!6U/Z?7*FADV(.Z/UX5.7,_QZAZB05[I: ^;:B
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M([GBT+/_]9N0>D:_5;] X%#XB<?7+7/;%C-5*.=XK'.CQZ3YT@NZ5Q-]J>#
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MD2L7<VNZ!00MZTJY;FF;VN%WY;:/9FM#A=4)8G(>AAX  U3>PG+MS[[BIT
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MR3$1<"#H+*8S2)[)(*Z,/Y=R,JI$>^WY_3L&L/)N )]J '7-VK']VP76S0!
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M[F%W IC&X>N%;V<P-8><#>9J+M)+.5?M>KZ)E%$I_:E<^?NZC?\ 4$L#!!0
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ML1Z3.J+R[M?[ZTGTTQ2S+)^^/T)OX%%DIBK7V?3R_='WBT\@/?KU^-6K=_\
MX*]_?SN-?LO5[;69EM%)841I='27E5=1>66B/_/B1_931&<34=J\N ;@N'[;
M27[S4&275V6$(8Z7PY:O%F]CR@E""02(& 2HLA9PB T05A@FJ(HEU*\OWPJ>
M*J@% DQR""@5"@BL!<#&Q$AR)3!7==!)-OWQMOHAQ<Q$SMYT5O_Y_NBJ+&_>
MCD9W=W=O[F4Q>9,7ER,,(1DM1Q\MAM]OC+\C]6C$.1_5KSX.G65- UU8-/KK
MC]-S=66N!<BFLU),524PR][.ZB=/<R7*NNH[\XI:1U1_@>4P4#T%$ 8$O;F?
MZ:/C5U$T+T>13\PW8Z/J]_=OGULE^:@:,9J:R^JS/3-%ENOS4A3EJ9!FXK*O
MHY4/-^;]T2R[OIF8Y7-7A;'-82=%L1:URI)76:*DRO*7-K%1C_3WE&^YF>L>
MDJOM?ME7CMMJ^F5OZ5ZX;PAS^(179'JG/#^@/D[U4,?NHU3OU ^?\;X.B[P4
MDP$.BR>9E90GU1.G[M%"I@JTY<NTUEE\=:^D:NY+,]5F_FVY%CK*]/LC]VBL
M339>SGN/'_5O+K$Q@]1"2R$0!KNYBS()4NTF)6)AK V!3%HQ+A\/ZK&9@N_G
M2_U:9(?"D8>WLH71PLSRVT+-9S>G6LWL\T2.'V?SN6CD5*-*]MWH*<.0NDP.
M[W9R6*.Y6@L]J2;KO'AN)E>[S3P=_3/GIG8R,^K-9?YSY-[K'&%2/0#5@_J@
M;X\XVO@L/A3+/$6A=I1M,6*D<K<2N2G!6@5MD5]W-%3F'3_&>>F<[%&4%]H4
M;GW98&'M<#HKS$E^[2(J4X6]J- LOEIKBC%/D;8H38&-N084BA@(ICG0RAJF
M,+46D:ZLM<L<&#@G#-2*<C27CFKM[M1M*=-N]/9CWH^_,-]>$.ZV%43BEK"#
MX;C;VBJ3'4;[@WF>3S*5E>ZT\ ]'>)&)R1C'3$)$*$BEP&[R0Q!(P1+ #%64
M\)AH#+L"N1G^P" ^"49+Q>[X-11C-W;]+/KAYN/."[)V$T%P-80;#*IV*ZLP
M;1GE#]%)5CY\*(PXR;49*T(2:Q(#3.S(H9IAD'("@664QY1QE.C.\]EJX .#
M4TE%E594B75G9LW[;EI"'?EQTM&,%R)-F0?!L19H,"R:TE\%HO%U?Q0^3LLJ
MD-;NTYF=Y3-W@O=W=E,?'):I5!MJ@0/$S2L66\"K<RR:(HEBDJ0VZ0Q&N\R!
M,9D+1POEU]%<.W+BGMQL*=1NBO9CWX^I4.=>D.TV%H3<EK"# ;C;VBJ.'4:'
MPGGB%H^%F'QVR\?[_YB'<<Q1:B'E (O4 )I8!20A,5 00FE@R@2*_;A\IC ,
MD@O1J%:-G*POB\_KTA7#'FZ#".QN- "]%C,]J'L><6#@6@QMLM8VL.<<6,VK
M7XN+_&[J0-,L9<@"+5C558Q3((B!@+EI4)"$8&IYT 3XI#'P[%>OL_(BJJ0#
MI[Z5^GC.>V&N^TUZG0R'SWB;EOI/=RLQ7V:NVS35.M$U# UH:1AU6[A '^_5
ME?LLS1=Q;<90$L&JQ:?&"0?4X!1(323 3!(D$$\QIYV;&@T"AVYK+"2CI694
MB7IT-IIJTJ&WT=.I9W?#SZ1?@V.+D[ 61U/ X9H<6^RLM3FVC0M'"V%YD943
M,S96$TAA C@Q$E!.&> Z=3\L213""B>J\SG=\^ '1JK6B'(;(?Q/^:]HJ>[/
MU&,QNO,48M&/)5]W03 ]M]$+I,=@@T/TW$830!MC_.'YT\4IS;3JX=].L_DF
MH=F8(IDPBR"(K4X U10#;F("&('"6H:93757@AH5#HS10C-:%^U.47-5=J/4
MVZL?3YXVO7#::B6(J>:(@X&UU= J7=L'^B-6[;V;G%WE4_/E]EJ:8APG-(YU
M0D!,4K?L@Y "F5+'F82*L215A'>FZWGP X-5RT6U7C07[ [51AUV\]3'G1]*
M'L:\,&IS$$301K#!X&FSL<I-ZQA_9"X*46T*/G^XEKD[0E)B#(,"8*T<+R36
M0$*+0 JMA"3!+%%I5U[6(A]Z,3?7BN9BW4%9=[^;DF!/GJNW;G:\\&A,/8B-
M]4B#@=%H8)6*Y@&A_;O/4Y47-WE13TKGI2C-27X[+8N'^AH-M#!5/$W<.HTP
M0&,(@;28 0&YD8A89K#UZ^5MU1NFK[>6PNNH3J+J=BT2";K"M;V,75M^>RM.
M4/NO5UT"NH&=W/;H#&Z//W"7L)/9S8YAM[?U;-[7<;\69T7^,W-VQEH+;>(4
M 942"BB+$1""Q4!JFEJF!<&J\]:H;4(#M_$?#^BE?F O_WFY/!OZ/8K0KZO?
MW7]X:[_%7/_^_O/ +]/D;['7VNEO&]][:_'GV>S6%*L[9Q&4D"DW56M%#* B
MT8 +'0.HL$P@TX82&;C!>$/LP.!N;+>=)["?W<:;E=O-[S[KX<=PKU+TV8#<
MZG$?VY W@[_49N16FUNV)+>_)V!/9?[3%!_DK"R$*L<D8=9R&P.3P&K'&!?N
MO%124)V2"DV%0M9TWE2Y&OG P-9:T7^7:O_SV%>YYG\WB<&N_+#K;,AO;V53
M\F&;*]<B#;>[LLG VO;*Q@&AR]./UZ:X=*>ZOQ?Y77GE$+P1TX<Q9U#IQ!@@
MDQ0#JI4!J90QB 6"!D*(#$5^J]-&G6$6ITOI:*X=+<1]5Z;-E>JZ,.WM/VA=
MZFL]8%&ZU5B/-6ESW(&7I%O-;:Y(MP_W1W1Y[]R%>^N8IZF0,7-K%>;6G=0J
M ;C%&"2Q2I2BR K8^0+$:N #0_AX7V6EY7_7:&U]-V2AAORHZN8EZ,;0U<1[
MW0]:!QK\-M#5])ON_EQ[W1^$#RZ&KN)\FHC+L94:8JC2ZF:R%- 8)4#&J3L-
M(\9*-T,I93I?6EB+?& 4'K6B2JP["^ON=\,0[,F/AHYVO'!H3#V(A_5(@P'1
M:&"5B.8!H<NW3]ED>6$V0<I20@1(":_V)4H-)(,),)18JQ#GU+>C^!1\F(5:
MI>=]@7JC#EU79&'N@I9A78P%++TV'?18;ZT$&WB1M6EC<V75,"84F0MQ_UD[
M_C*[V":R.&X,@8KHF ,$-:Z:>S%(C<4@I:E026)5G# _?EJ4AH')B4?KZH%H
MM=6K*V=[J$(0=/X%"$!PA[D>/+9%'AC.'08W2=WUAI[7T1:_3K.I06/,,4?8
MQ,# 6%1[AC'@C"$04X(Y498IWKF7UZHR\!6TQ8.HTHZ^3D,OH*W5J2NJ/=T'
M8>IO//S*69.Q_I?-UJ*^S#6S)F.M%\P:!^\/2SSF2<R1%2G0B66 DE0":9 !
MAAFN)3$0,\_;0!M47A++B[N\/Y:X!Y9>[O>(Y3;C>\$2'P1+_/)88A\L\0&P
M)&/J3A"MD0FPDCLL*2;N!-$D@!"9:LDPP7'8?TU857E1+-U!LX?YDO0 T\O_
M/L'<:GTO:)*#H$E>'DWB@R;IC>8W<YE5%^^F97WK)",:41%K@"U) 952N36L
M<) 2ACB2<0J3SK>3-@D, ^23IN?MI(TUZ<I?N-,@]+J:#,"MV4D/TIX%'!BR
M9CN;?+6,:T-KM>(.QA_'KY;/9//_;WW\ZO]02P,$%     @ \X!;6GZ8'P,9
M!P  V#4  !4   !S>7)E+3(P,C4P,C(W7W!R92YX;6S5FUM3W,82Q]_]*?:0
MUS/LW"^438I#[%-42$S9I)+*R]9<>A95M!*E%0:^_6D)U@8#.3+:%/(+NRN-
MU-/__JFGU1*O?[Q:E;-/T*R+NGJSPW;IS@RJ6*>B6K[9^>WT';$[/^Z_>O7Z
M7X3\\9\/Q[.?ZGBQ@JJ='3;@6TBSRZ(]F[5G,/N];OXJ/OG92>G;7#<K0O;[
MPP[K\^NF6)ZU,TZYV@S;[&WVE'2",4T)$\"(C#D31SD0GST8+Z,*-/U[N>>=
MC31Y1DQPE$CI(_$\><(!% LN>NYB?]*RJ/[:Z_X$OX89NE>M^Y]O=L[:]GQO
M/K^\O-R]"DVY6S?+.:=4S#>C=VZ'7ST8?RGZT<PY-^_W?AZZ+AX;B*=E\S]^
M.?X8SV#E25&M6U_%SL"ZV%OW&X_KZ-M>]?\[K]F3([I?9#.,=)L(XT2PW:MU
MVME_-9O=R-'4)7R /.L^?_MP]-GD&D,#N[%>S;L]\\,:23CQRVZ>_7'M]3F\
MV5D7J_/R\[:S!C)NPP-)%U#*N>FL_?#EX/D7P^<-K)&6WM%CW'![CL[:-TX"
MKEJH$MQXM3E]6<=[@\I.T[K9'%GZ &6_=9&@6/1G/@CKMO&Q76B=A*&"$P@.
MB PBD1"B)$XF1YVSG$&^[W,WWS5.N _!&N+NLOXTQQ-C*+CHOG2"B%Z,!^9N
M1'G>O#?7W"F.73"1&:7<$)FU)I([2:R&2#1707.?C14P:MIWK=V?]=U@'C1Q
M5C<)&DP:&W.^B?<"^Q#7VQ'S<]_@B4@\*\JT.3HW]6H;L6KK+2AW$Q:<[LX,
MO<[0-)".;Z+RI'.]9RVF4NA'CHGXVZHMVNL/L"PZ :KV5[^"!>9#I9D2Q(/T
M1%HKB.7!$8@J&FN<4=2,BOQC5@<1P*=+P&@E)T'"$2[)S7G=],)_1/WAL+ZH
MVN;ZL$ZPB%X)2%D0$6Q&L*4AUE%/<E1,:Y!91;\%,/YV$H,X$5/G9'LZ3P*;
M=T4)OUZL C0+GYFE(7H2O<4J*P1.''>!V, -*&\@!;L%1KY8' 2$G#H0SU1P
M$M$_]5='";4J<G%3:=XZ@HZGQ'4DF:,.,G&&>3!C'N2 F\%+!GH+*#QA?A 7
M:NI<;$/;24!RD!*&8'W[@24ZL$4V3)FH\3XL"2R4*'-(.JZ1,B?F 9-@W@H@
MCY@>!(>>.AQC-9TH&!PK:&6=")(H2#AUJ23QU$C"L^06H@M&BG\$##X(#//]
M@?%MFDX4#+'@ "R!H$2C.$0:CFNC2XXHY;-$R5 V^H^ (0:!8;\_,+Y-TRF!
M<8A?WS>G]66UH#PI*80AR0J++J2.;2R8@9FD)6/2L6W<L3XP/ @*]YU \4P]
MIX1$?R?UOCEIZD]%%?%&RBGT'#.=Q>S7Y3P@@8M I) 0=%(<.-\>%U]9'];3
MHM\)'6.DG1(B)_6Z]>6?Q7E_IRV &^IX() E>A&%(]9&BD[YY"62SOBXWNS3
MMH?A,>&>YY9D?6$XNJQWT(#OYVTR9KD0%7$Z8O$<340I4L8T:*S*4C WLNZ\
M:VT8 !-N>3Y;NA<.>?= K#PYJZM-QP6]C4YS2ZC5N-PYHPE22HDQT7&%UH,+
MH\+^M<5AH9]P%W.4A"\<_M^;HFVA.JQ7JXOJMJNR7GB=N#-4$ZQYL0H6&HB/
MU!%C#2C%C*)LW*7_J-EA($RX>SE>S!>FX6-=%K%HBVKY"Q8X3>'+!0]>"P-(
ML#.B8QD7+H%44V\=EX)K9\<]^7QH<Q@'$^Y6CI3QA2$X:: C&+"P[9_B=B\
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M_5?_ U!+ 0(4 Q0    ( /. 6UHPV!WD_"D   #, 0 9              "
M 0    !S<'ER92TR,#(T,3(S,7AE>'@Y.3$N:'1M4$L! A0#%     @ \X!;
M6KN%)PO'#P  ;GH  !$              ( !,RH  '-Y<F4M,C R-3 R,C<N
M:'1M4$L! A0#%     @ \X!;6GO+-IEB @  \08  !$              ( !
M*3H  '-Y<F4M,C R-3 R,C<N>'-D4$L! A0#%     @ \X!;6@K#:W2X"@
MKUP  !4              ( !NCP  '-Y<F4M,C R-3 R,C=?;&%B+GAM;%!+
M 0(4 Q0    ( /. 6UI^F!\#&0<  -@U   5              "  :5'  !S
J>7)E+3(P,C4P,C(W7W!R92YX;6Q02P4&      4 !0!+ 0  \4X

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>syre-20250227_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="syre-20250227.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636282</identifier>
        </entity>
        <period>
            <startDate>2025-02-27</startDate>
            <endDate>2025-02-27</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-24">0001636282</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-02-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">SPYRE THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37722</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">46-4312787</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">221 Crescent Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Building 23</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="c-1" id="f-9">Suite 105</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">02453</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">651-5940</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-19">Common Stock, $0.0001 Par Value Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-20">SYRE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-21">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
